Shanghai Henlius Biotech, Inc. (HKG:2696)
33.05
-0.95 (-2.79%)
Apr 3, 2025, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B CNY with 6.11% growth. Shanghai Henlius Biotech had revenue of 2.98B in the half year ending December 31, 2024, with 54.69% growth.
Revenue
5.72B CNY
Revenue Growth
+6.11%
P/S Ratio
2.95
Revenue / Employee
1.63M CNY
Employees
3,515
Market Cap
17.96B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sino Biopharmaceutical | 30.72B |